XML 60 R48.htm IDEA: XBRL DOCUMENT v3.21.1
License Agreement Revenue - Additional Information (Detail) - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Feb. 28, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Income tax expense $ 1,100,000 $ 0  
Exclusive License And Collaboration Agreement      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Non refundable upfront payment received 10,000,000.0    
Transaction price 12,100,000    
Fixed upfront cash payment 10,000,000.0    
Amount related to withholding tax obligations 1,100,000    
Revenue recognized 1,100,000    
Income tax expense 1,100,000    
Exclusive License And Collaboration Agreement | Maximum      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Potential development and commercial milestones yet to receive     $ 110,000,000.0
Asset Purchase Agreement | Cypralis Limited      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Revenue recognized 0    
License Agreement | Waterstone Pharmaceutical HK Limited      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Revenue recognized $ 0